T A B L E O F C O N T E N

Search methods
In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 10, 2012, in The Cochrane Library; MEDLINE (Ovid SP, 1966 to November 2012 ; EMBASE (Ovid SP, 1980 to November 2012 and CINAHL (EBSCOhost,1982 to November 2012) for published studies. In our original review, we searched until May 2004.
Grey literature was identified by searching conference proceedings and trial registries and by contacting experts in the field.
Selection criteria
As in the original review, review authors selected randomized controlled trials that compared PLV with other forms of ventilation in adults (16 y of age or older) with ALI or ARDS, reporting one or more of the following: mortality; duration of mechanical ventilation, respiratory support, oxygen therapy, stay in the intensive care unit or stay in hospital; infection; long-term cognitive impairment or health-related quality of life; long-term lung function or cost.
Data collection and analysis
Two review authors independently evaluated the quality of the relevant studies and extracted the data from included studies.
Main results
In this updated review, one new eligible study was identified and included, yielding a total of two eligible studies (including a combined total of 401 participants). Of those 401 participants, 170 received 'high'-dose partial liquid ventilation (i.e. a mean dose of at least 20 mL/kg), 99 received 'low-dose' partial liquid ventilation (i.e. a dose of 10 mL/kg) and 132 received conventional mechanical ventilation (CMV). Pooled estimates of effect were calculated for all those who received 'high'-dose PLV versus conventional ventilation. No evidence indicated that 'high'-dose PLV either reduced mortality at 28 d (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.79 to 1.85, P = 0.37) or increased the number of days free of CMV at 28 d (mean difference (MD) -2.24, 95% CI -4.71 to 0.23, P = 0.08). The pooled estimate of effect for bradycardia in those who received PLV was significantly greater than in those who received CMV (RR 2.51, 95% CI 1.31 to 4.81, P = 0.005). Pooled estimates of effect for the following adverse events hypoxia, pneumothorax, hypotension and cardiac arrest all showed a nonsignificant trend towards a higher occurrence of these events in those treated with PLV. Because neither eligible study addressed morbidity or mortality beyond 28 d, it was not possible to determine the effect of PLV on these outcomes.
Authors' conclusions
No evidence supports the use of PLV in ALI or ARDS; some evidence suggests an increased risk of adverse events associated with its use.
P L A I N L A N G U A G E S U M M A R Y
No evidence of benefit of partial liquid ventilation in adults with acute lung injury and some evidence of increased risk associated with its use
Seriously ill adults can get a severe lung disease called acute lung injury or acute respiratory distress syndrome, which stops enough oxygen from getting into the blood. About half of these patients die, and for those who survive, it can take several years to get back to near normal.
At the height of their illness, many of these patients are unable to breathe properly and need the assistance of a breathing machine called a ventilator, which pushes gas into the lungs under pressure through a process called artifical ventilation. Artifical ventilation can cause further damage to the lungs. The need to support breathing for these patients, while avoiding further lung damage, has led to a search for gentler types of ventilation.
One such gentler type of ventilation is called partial liquid ventilation. It uses a special liquid called perfluorocarbon instead of the gas used by traditional ventilators.
The purpose of this systematic review was to determine whether patients with acute lung injury who received partial liquid ventilation were less likely to die or were more likely to recover completely than those who received traditional gas ventilation. 1.The 'low' quality grade was assigned on the basis that only two studies were eligible for inclusion in this meta-analysis, limiting the quantity of data available for analysis, and based on the fact that both studies excluded those with severe nonpulmonary organ dysfunction, limiting the generalizability of these results.
Partial liquid ventilation
B A C K G R O U N D Description of the condition
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are characterized by the development of noncardiogenic pulmonary oedema and hypoxaemia (Bernard 1994) . By definition, it is a secondary illness, occurring in response to an initial primary illness or insult, including severe pneumonia, pancreatitis, sepsis, trauma, shock and massive blood transfusion (Bernard 1994; Raneiri 2012 
Description of the intervention
Partial liquid ventilation has been proposed as a possibly beneficial form of ventilatory support in ALI (Wiedemann 2000) . Using liquids to facilitate gas exchange was first proposed in the 1960s, when Kylstra and colleagues showed that mammals could breathe in a liquid medium (Kylstra 1962) . Initial experiments using saline required hyperbaric conditions to dissolve enough oxygen in solution (Kylstra 1962) . This led to a search for fluids that could carry large amounts of oxygen and carbon dioxide at atmospheric pressure. Only silicone oils and perfluorocarbons were found to have these properties, and as silicone oils proved toxic, only perfluorocarbons were investigated further (Clark 1966 
How the intervention might work
The rationale for the use of PLV in ALI centres on the physical properties of perfluorocarbons, which make them particularly useful in the context of increased surface tension at the air-gas interface, which occurs in this condition (Kaisers 2003; Matthay 2011) . The very low surface tension of PFCs gives them surfactant-like properties, thereby improving lung compliance. Twice as dense as water, they gravitate to dependent regions of the lung, reopening collapsed alveoli and acting as liquid positive end-expiratory pressure (PEEP) (Davies 1999; Kaisers 2003) . Perfluorocarbons are thought to improve ventilation/perfusion matching by compressing blood vessels (through PFC-filled alveoli) in dependent regions of the lung, with consequent diversion of blood flow to the gas-filled alveoli in nondependent regions (Davies 1999; Kaisers 2003 
O B J E C T I V E S
The primary objective of this review was to assess whether PLV reduced mortality (at 28 d, at discharge from the intensive care unit (ICU), at discharge from hospital and at one, two and five years) in adults with ALI or ARDS when compared with conventional ventilatory support.
Secondary objectives were to determine how PLV compared with conventional ventilation with regard to duration of invasive mechanical ventilation, duration of respiratory support, duration of oxygen therapy, length of ICU stay, length of hospital stay, incidence of infection,long-term cognitive impairment, long-term health related quality of life, long-term lung function, long-term morbidity costs and adverse events. The following adverse events were considered: hypoxia (arterial PO 2 < 80 mm Hg), pneumothorax (any air leak into the pleural space requiring therapeutic intervention), hypotension (systolic blood pressure < 90 mm Hg sustained for longer than two minutes or requiring treatment with fluids or vasoactive drugs), bradycardia (heart rate < 50 beats per minute sustained for longer than one minute or requiring therapeutic intervention) and cardiac arrest (absence of effective cardiac output).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs.
Types of participants
We included mechanically ventilated adults with ALI ± ARDS. We defined adults as persons aged 16 y or older. ALI and ARDS were defined according to American European Consensus Conference (AECC) criteria (i.e. the definition in use until 2012). Definition of ALI (Bernard 1994):
• Acute onset of respiratory failure;
• Bilateral opacities on chest x-ray (CXR) consistent with pulmonary oedema;
• Pulmonary artery wedge pressure < 18 mm Hg or no clinical evidence of raised left atrial pressure; and
• Partial pressure of oxygen in the blood (PaO 2 )/fraction of inspired oxygen (FiO 2 ) ratio ≤300 mm Hg.
Definition of ARDS (Bernard 1994):
• Bilateral opacities on CXR consistent with pulmonary oedema;
• PaO 2 /FiO 2 ≤ 200 mm Hg.
Types of interventions
PLV compared with other forms of ventilatory management without the use of PFC.
Types of outcome measures
One or more of the following outcomes must be reported.
Primary outcomes
• Mortality (at 28 d, at discharge from ICU, at discharge from hospital and at one, two and five years).
Secondary outcomes
• Duration of invasive mechanical ventilation (i.e. duration of ventilatory support delivered via endotracheal tube or tracheostomy).
• Duration of respiratory support (i.e. duration of any form of artifical support with ventilation, including both invasive ventilation as defined above and noninvasive ventilation delivered via face mask, nasal mask or hood.
• Duration of oxygen therapy.
• Length of stay in the ICU.
• Length of stay in hospital.
• Infection (sepsis, pneumonia).
• Long-term cognitive impairment.
• Long-term health-related quality of life.
• Long-term lung function.
• Long-term morbidity costs.
• Adverse events.
Search methods for identification of studies Electronic searches
In 
Data collection and analysis
Selection of studies
Two review authors (IMG and AS) independently selected studies according to the following process. We assessed each title and abstract retrieved by the search strategy to determine whether they met the eligibility criteria for inclusion. We excluded studies that were clearly ineligible (animal studies and those addressing interventions other than liquid ventilation) at this stage. For all other studies, we examined full-text versions to determine eligibility. We assessed methodological quality using the criteria detailed above, and the study was excluded or accepted for inclusion. We resolved any discrepancies by discussion between these two review authors. One review author (IMG) was responsible for contacting primary study authors when additional details were required for determination of study eligibility and quality.
Data extraction and management
A comprehensive data extraction form was designed by one review author (IMG), using all items in the checklist recommended in Section 7 of the Cochrane Handbook of Systematic Reviews for Interventions (Higgins 2011) . Two review authors (IMG and AS) independently extracted data. We entered data initially onto the data extraction form and then into the appropriate fields in RevMan.
RevMan entries were checked against the primary study report by two review authors (IMG and AS).
Assessment of risk of bias in included studies
The risk of bias in included studies was assessed independently by two review authors (IMG, AS), using the Cochrane Collaboration tool for assessing risk of bias, as described in Section 8 of the Cochrane Handbook of Systematic Reviews for Interventions (Higgins 2011). We resolved any discrepancies by discussion between the assessing review authors. For each included primary study, bias was assessed in the domains detailed below. For each domain, we determined the risk of bias as 'high', 'low' or 'unclear', and each judgement was supported by direct quotes from the primary reports, where applicable.
Random sequence generation
• Probably done/low risk: where the study report described a random method of sequence generation.
• Probably not done/high risk: where the study report did not describe a random method of sequence generation.
• Uncertain/unclear risk: where the study report did not provide enough information to reveal whether or not a random method was used.
Allocation concealment
• Probably done/low risk: where the study report described a centralized method of intervention allocation or a method by which investigators could not feasibly foresee the treatment assignments of individual participants.
• Probably not done/high risk: where the study report did not describe a centralized method of intervention allocation or a method by which investigators could not feasibly foresee the treatment assignments of individual participants.
• Uncertain/unclear risk: where the study report did not provide enough information to reveal whether or not the method used was likely to ensure allocation concealment.
Performance bias
• Blinding of participants and personnel.
• Probably done/low risk: where the study report described blinding of participants and key study personnel.
• Probably not done/low risk: where the study report did not describe a blinded method, or blinding was incomplete but measures were taken to ensure and determine equality of ancillary treatment between groups.
• Probably not done/ high risk: where the study report did not describe a blinded method, or blinding was incomplete and measures were not taken to ensure and determine equality of ancillary treatment between groups.
• Probably not done/ unclear risk: where the study report did not describe a blinded method, or blinding was incomplete and the authors did not describe measures taken to ensure and determine equality of ancillary treatment between groups.
Detection bias
• Blinding of outcome assessment.
• Probably not done/low risk: where the study report did not describe a blinded method, or blinding was incomplete but outcome measures addressed were objective.
• Probably not done/ high risk: where the study report did not describe a blinded method, or blinding was incomplete and outcome measures addressed were subjective.
• Probably not done/ unclear risk: where the study report does not provide enough information to reveal the extent or adequacy of blinding or its likely impact on outcome assessment.
Attrition bias
• Incomplete outcomes data.
• Low risk: no missing outcome data for prespecified outcomes, or missing data equally balanced between groups, or reasons for missing data unlikely to be related to the intervention or to the outcome or unlikely to have a significant influence on the effect estimate or missing data dealt with by using appropriate imputation methods.
• High risk: missing data for prespecified outcomes and any of the following missing data unequally balanced between groups, or reasons for missing data likely to be related to the intervention or to the outcome or likely to have a significant influence on the effect estimate or missing data not dealt with by using appropriate imputation methods.
• Unclear risk: the study report does not provide enough information to reveal the extent of missing data or the influence of missing data on study results.
Reporting bias
• Outcome reporting bias.
• Low risk: all prespecified outcomes reported completely.
• High risk: one or more prespecified outcomes not reported or reported incompletely.
• Unclear risk: not enough information to reveal the adequacy of outcome reporting.
Other bias
• Low risk: no other potential source of bias identified.
• High risk: other potential sources of bias identified.
• Unclear risk: report not complete enough to allow accurate determination of the presence or absence of other sources of bias.
Measures of treatment effect
We performed the meta-analyses using Review Manager software (RevMan 5.1). We included two eligible studies and compared all participants who received similar dosages of perflurocarbon with those who received conventional mechanical ventilation. We used a random-effects model and calculated categorical outcomes as risk ratios (RRs) and continuous outcomes as mean differences (MDs), with 95% confidence intervals (CIs) for both.
Unit of analysis issues
None identified.
Dealing with missing data
For all missing data, we planned to determine whether data were 'missing completely at random', missing at random' or 'missing not at random'. Data were judged to be 'missing completely at random' and 'missing at random' if the reasons the data were missing were 'highly unlikely' and 'unlikely', respectively, to be related to the intervention or the outcome being addressed. Data were judged to be 'missing not at random' if the reason the data were missing was 'likely' related to the intervention or to the outcomes being addressed. For data judged to be 'missing not at random', we planned to determine the degree of influence this was likely to have on the effect estimates from the study and on the adequacy of statistical measures used to take account of the missing data. Where appropriate alternative analyses were used to take account of missing data, we planned to use effect estimates from those analyses to contribute to our pooled estimates of effect. We planned to discuss all available details regarding missing data and the likely impact of this on the findings of this review, and, if appropriate, to conduct a sensitivity analysis to evaluate the potential impact of incomplete outcome data on the pooled estimate of effect.
Assessment of heterogeneity
Included studies were assessed for clinical heterogeneity by comparing the following factors: study participants, setting, interventions and ancillary treatments. Methodological heterogeneity was assessed by determining and comparing the risk of bias in included studies. Where included studies were adequately homogenous in terms of clinical and methodological aspects, statistical heterogeneity was assessed by performing a visual inspection of forest plots and the Chi 2 test (assessing the P value) and by calculating the I 2 statistic. A P value less than 0.10 and I 2 in excess of 50% were taken as indicative of significant heterogeneity.
Assessment of reporting biases
To determine the presence or absence of reporting bias, we planned to examine funnel plots for each meta-analysis that included ten or more studies to determine if they were symmetrical. Where plots were visually asymmetrical, the meta-analysis was judged to be potentially biased because of small study effects or reporting bias.
Data synthesis
It was planned that a meta-analysis would be performed if all of the following conditions were met:
• No significant clinical or statistical heterogeneity of the included studies;
• Inclusion of at least two eligible studies deemed to have low individual risks of bias; and
• No substantial reporting bias.
Subgroup analysis and investigation of heterogeneity
If adequate numbers of eligible studies were identified (at least three), we planned to perform subgroup analyses to determine whether the results differ by:
Population:
• Age;
• Severity of overall illness (e.g. Acute Physiology and Chronic Health Evaluation (APACHE) score or Simplified Acute Physiology Score (SAPS)) or severity of ALI or ARDS; and
• Aetiology of ALI or ARDS (e.g. septicaemia, pneumonia, trauma, burns).
Mortality and other outcomes have been shown to vary by the age of the patient, the initial severity of ALI or ARDS or of the patient's condition (e.g. by APACHE score) and the underlying cause of ALI or ARDS (Monchi 1998; Suntharalingam 2001; Ware 2000) .
Intervention:
• Initial amount or dose of perflurocarbon (PFC); • Whether continuous PLV or intermittent doses of PFC are used; and
• Type of PFC (e.g. perflubron, Rimar).
The optimal dose of PFC that should be used when PLV is initiated is unknown. Variations in the technique of PLV may also include giving an initial dose of PFC with or without further top-up doses to maintain partial filling of the lungs. Various types of PFC with different physical and chemical properties may be used (Davies 1999).
Co-interventions used in addition to PLV:
• Inhaled nitric oxide;
• Surfactant;
• The prone position; and • High-frequency ventilation.
Whilst the mainstay of treatment for ALI or ARDS is mechanical ventilation, additional therapies have been considered, and some of these have been subjected to RCTs. Adjuncts to mechanical ventilation have included inhaled nitric oxide, endogenous surfactant, prone positioning and high-frequency ventilation (Conner 2000) ; all can be used in conjunction with PLV.
Sensitivity analysis
If adequate numbers of eligible studies of good methodological quality were identified (three or more), we planned to conduct the following sensitivity analyses to test how robust our findings are under the following conditions:
• Analysis excluding all studies considered to be at high or unclear risk of bias; and
• Analysis excluding studies with missing data considered to be 'missing not at random'.
R E S U L T S Description of studies
Results of the search
In combining our original searches from the period 1966 to May 2004 with updated searches covering the period from May 2004 to November 2012, we retrieved a total of 749 citations. We reviewed the titles and abstracts and excluded 739 citations at this stage, as it was clear from the abstract that they would not be eligible for inclusion. These included in vitro and animal studies, studies of interventions other than liquid ventilation, studies not performed in adults, review articles, commentaries and duplicate reports . Of the remaining 10 articles, we excluded seven, as they were not randomized controlled trials; one was excluded because it had not yet been completed, and the remaining two were found to be eligible for inclusion (Figure 1) .
Included studies
Two studies were eligible for inclusion in this updated review. The first study (Hirschl 2002) was the only study included in the original review because although the second study (Kacmarek 2006) had been completed at the time the original review was conducted, the results were not published until 2006. The study included in the original review (Hirschl 2002) was a multi-centred RCT conducted between July 1995 and August 1996 at 18 centres in North America. This was a pilot study that sought to evaluate the safety and efficacy of PLV in adults with ARDS. The mean dose of PFC used was 22 mL/kg. As detailed below (Characteristics of included studies), this study raised some concerns related to changes in oxygenation criteria for recruitment and the exclusion of patients with multiple organ failure, both of which may influence the generalizabilty of results. The additional study included in this review (Kacmarek 2006) was a multi-centred RCT that was conducted at 56 centres in Europe and North America between December 1998 and December 2000. It enrolled 311 participants, achieving its target sample size, although the sample size was changed on two occasions in response to protocol amendments and interim analyses. Investigators evaluated two doses of PFC 'low dose' of 10 mL/kg and 'high dose' of 20 mL/kg using a control group that received CMV alone. All three groups received standardized ventilatory support, target gas exchange criteria for weaning were defined clearly a priori and the numbers of weaning attempts per day were equal between groups when these criteria were met and were not met. The study was generally well conducted and was clearly reported. The long period between the end of the study and publication of results, as highlighted by the authors, emphasizes the problems associated with publication of negative trials and the importance of negative results to medical knowledge. For both studies, participant follow-up appeared complete, and no missing data were identified. Neither of the included studies (Hirschl 2002 ; Kacmarek 2006) addressed mortality beyond 28 d, duration of stay in intensive care or of stay in hospital, morbidity, quality of life or cost-effectiveness.
Excluded studies
We excluded a total of seven completed studies from the review. Details of these are provided in the Characteristics of excluded studies table. Apart from one new included study (Kacmarek 2006) , no new completed human adult studies in ARDS/ALI participants of any design were identified in the new search (May 2004 to November 2012). Most reports on PLV were animal studies, review articles, letters or commentaries.
Risk of bias in included studies
We assessed risk of bias using the methods detailed above. We have detailed the results in the Characteristics of included studies section and have summarized them in Figure 2 and in Figure 3 . 
Allocation
In the study by Hirschl and colleagues (Hirschl 2002) , the allocation sequence was generated randomly, and a centralized intervention assignment was used. These factors reduced the risk of selection bias. However, participants randomly assigned to PLV were randomly assigned on average 25 hours after other participants were randomly assigned to conventional ventilation. Those in the PLV group therefore had a longer duration of mechanical ventilation before randomization and may have been at a different stage in their disease process compared with those in the conventional ventilation group.The trial by Kacmarek and colleagues (Kacmarek 2006) used a randomized computer method to generate the allocation sequence. Methods used to ensure allocation concealment are not detailed in the trial report. The corresponding author was contacted for clarification, but no further information was obtained. However, given that a computer generated method of allocation was used, the overall risk of selection bias due to these elements was judged to be low.
Blinding
Neither of the two included studies (Hirschl 2002; Kacmarek 2006) used blinding of participants or of key study personnel. However, given that the outcome measures of both studies were unambiguous and objective, the lack of blinding alone is unlikely to have had a significant impact on outcome ascertainment. In the study by Hirschl (Hirschl 2002), investigators did have access to the interim data and were aware of the preliminary results. It was on this basis that they decided to change the inclusion criteria. Also although ventilation management guidelines were provided, no measures were taken to ensure or to measure adherence to these guidelines, and no guidelines were provided regarding the discontinuation of PLV. It is therefore possible that participants may not have been treated equally with respect to ventilation management, weaning decisions and discontinuation of PLV.
Incomplete outcome data
The outcome data were assumed to be complete for both included studies based on the fact that all enrolled participants were followed up in both studies. The study by Kacmarek (Kacmarek 2006) provides a clear statement of follow-up: "311 patients who were enrolled were followed up for the 28 day study period". The trial by Hirschl (Hirschl 2002) does not provide such a statement but does provide enough information, based on adverse event data to allow the reasonable assumption that all enrolled participants were followed up for outcome assessment.
Selective reporting
No selective reporting bias was judged to be present in either of the two included studies (Hirschl 2002; Kacmarek 2006) .
Other potential sources of bias
The risk of bias from other sources was judged to be low in both studies (Hirschl 2002; Kacmarek 2006) .
Effects of interventions
See: Summary of findings for the main comparison The two identified eligible studies addressed similar populations, interventions and outcomes and were therefore reasonably clinically homogenous.The trial by Kacmarek (Kacmarek 2006) employed two doses of PLV a higher dose of 20 mL/kg and a lower dose of 10 mL/kg. Only the higher dose was used to calculate pooled estimates of effect for the outcomes below, as the lower dose was substantially less than the mean dose of 22 mL/kg used in the trial by Hirschl (Hirschl 2002). Assessment of statistical heterogeneity is limited by the small number of included studies, but the CIs for all comparisons overlap, and I 2 values were 0 and 20% for 28 mortality-free and ventilator-free days, respectively. Mortality The overall pooled estimate for the RR of mortality at 28 d of PLV was 1.21 (95% CI 0.79 to 1.85, P = 0.37) (Figure 4) . Both included studies suggested a trend towards higher mortality when PLV was used, but neither study showed a significant difference. Hirschl 2002 reported a 28 day mortality of 36% in the CMV group and of 42% in the PLV group (RR of death with use of PLV 1.15, P = 0.63). Kacmarek 2006 showed a 28 day mortality of 15% in the CMV group compared with 26.3% in the low-dose PLV group (RR 1.75, P = 0.06) and 19% in the high-dose PLV group (RR 1.27, P = 0.39). Duration of ventilation 'Days free of mechanical ventilation' was used in both eligible trials as a measure of duration of ventilation. The overall pooled estimate of the effect of PLV on days free of mechanical ventilation at 28 d was an MD of -2.24 (95% CI -4.71 to 0.23, P = 0.08) ( Figure 5 ) . , MD 5.6 d, P < 0.001) and in the high-dose PLV group (high-dose PLV = 9.9 d (SD 9.1), MD 3.10, P = 0.043).Time to unassisted ventilation was significantly shorter in the CMV group than in both the low-dose PLV group (12.5 vs 18.9 days, MD 6.2 d, P < 0.001) and the high-dose PLV group (12.5 vs 13.9 d, MD 1.4 days, P = 0.017). Also the percentage of participants alive and off ventilation at 28 d was significantly greater in the CMV group than in the low-dose PLV group (76% vs 53%, P < 0.001) or the high-dose PLV group (76% vs 61%, P = 0.027).
Adverse events
Both studies reported data on the following adverse events: hypoxia, pneumothoraces, hypotension, bradycardia and cardiac arrest. Pooled estimates of effect were calculated for each of these outcomes. The RR of bradycardia in those who received PLV was 2.51 (95% CI 1.31 to 4.81, P = 0.005) (Figure 6 ). Pooled estimates for other adverse events in those who received PLV were as follows: hypoxia RR 1.77 (95% CI 0.97 to3.24, P = 0.06), pneumothorax RR 2.06 (95% CI 0.71 to 5.95, P = 0.18), hypotension RR 1.38 (95% CI 0.87 to 2.18, P = 0.22), cardiac arrest RR 1.31 (95% CI 0.56 to 3.04, P = 0.54). Both included studies reported high numbers of PLV-related adverse events. Kacmarek reported statistically significantly more adverse events in those receiving PLV (Kacmarek 2006) and noted that most episodes of hypoxia and hypotension occurred during the first five days of drug delivery; investigators attributed these events to the need to interrupt ventilatory support to administer the PFC. A similar observation was made by Hirsch, with most adverse events occurring at the time of PFC dosing (Hirschl 2002).
Other outcomes
Duration of respiratory support, duration of oxygen therapy, length of stay in the ICU, length of stay in the hospital, infection (sepsis, pneumonia), long-term cognitive impairment, long-term health related quality of life, long-term lung function and costs were not addressed by either trial.
D I S C U S S I O N Summary of main results
Mortality
This review suggests a trend toward higher 28 day mortality with the use of PLV versus CMV; however, the difference did not reach statistical significance (RR 1.21, 95% CI 0.79 to 1.83, P = 0.37).
Duration of ventilation
Similarly, this review suggests a trend toward fewer ventilator-free days when PLV versus CMV is used (MD 2.24 d, 95% CI 4.71 to -0.23, P = 0.08).
Adverse events
Participants who received PLV were significantly more likely to suffer bradycardia (RR 2.51, CI 1.31 to 4.81, P = 0.005), and the pooled estimates of effect for other adverse events uniformly suggested trends toward higher risk for those receiving PLV, but these findings were not statistically significant.
Overall completeness and applicability of evidence
The findings of this review are subject to the following important limitations. First, there is a lack of evidence. Only two studies were eligible for inclusion in this review (Hirschl 2002; Kacmarek 2006) . Second, both studies used ventilator-free days as the primary endpoint. Ventilator-free days is a rather ambiguous concept that when used as a primary outcome measure carries an unacceptably high risk of showing that a treatment that increases mortality is actually superior (Schoenfeld 2002) ; it is an outcome of dubious clinical relevance. Although 28 day mortality serves as a slightly more informative outcome measure, it provides vital outcome information only up to this limited time point. Neither study measured morbidity, which is known to be substantial and persistent in survivors of ALI/ARDS (Herridge 2011). Unfortunately, the current ongoing study of PLV in adults with ALI is assessing the oxygenation index and pulmonary mechanics as primary outcome measures, with survival again reported as a secondary outcome measure (Chen 2011 
Quality of the evidence
The quality of both studies was reasonable in terms of risk of bias; however, both studies were subject to the limitations detailed above. Futhermore, both studies excluded patients with severe nonpulmonary organ dysfunction, limiting the generalizabilty of their results and hence of the results of this review .
Potential biases in the review process
Every effort was made to minimize selection and reporting bias by comprehensively searching both mainstream and grey literature to identify all relevant studies, with two review authors (IMG and AS) separately applying a priori defined selection criteria to select appropriate studies for inclusion. The small number of eligible studies may contribute to content bias. The findings of this review and meta-analysis need to be interpreted in the light of these limitations.
Agreements and disagreements with other studies or reviews
The findings of this review are consistent with those of existing studies in humans, namely, that PLV has not been shown to offer any survival benefit over CMV in participants with ALI and ARDS. On the basis of results of the most recent human studies, PLV in fact may be inferior to CMV, and it may be associated with increased risk of adverse events (Kacmarek 2006; Hirschl 2002 
A U T H O R S ' C O N C L U S I O N S Implications for practice
No evidence supports the use of PLV in adults with ALI or ARDS, and some evidence suggests that PLV may be associated with increased risk of adverse events.
Implications for research
Although no current evidence supports the use of PLV in practice, available evidence is limited. Further clinical research may therefore be appropriate but would require very careful monitoring for adverse events and would be most informative if it employed the current definition of ARDS and lung protective ventilation strategies, and if it addressed morbidity as well as mortality beyond 28 d.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Hirschl 2002
Methods Multi-centre, randomized controlled trial Done between July 1995 and August 1996
Participants 90 participants with ALI/ARDS from 18 centres in the USA Inclusion criteria:
• Bilateral infiltrates on CXR for ≤ 5 d;
• Mechanically ventilated for ≤ 5 d;
• FiO 2 ≥ 0.5;
• PaO 2 /FiO 2 ratio > 60 and < 300, irrespective of the level of positive endexpiratory pressure; and
• Aged 15 to 75 y. The first 45 participants were stratified according to Murray lung Injury score ≤ 2.5 or > 2.5. They had their PaO 2 /FiO 2 ratios determined at an FiO 2 of 1 The second 45 participants also had to have an APACHE 2 score of < 30. They had their PaO 2 /FiO 2 ratios determined at an FiO 2 of ≥ 0.5 Exclusion criteria:
• On ventilator support for diagnosed ALI/ARDS or with FiO 2 > 0.4 for longer than 24 h;
• On ventilator support for reasons other than diagnosed ALI/ARDS for longer than three days in the previous 21 d;
• Tidal volume < 4 mL/kg; • Neuromuscular respiratory failure or cardiac disease causing the compromise in gas exchange;
• Lung parenchymal or airway surgery within 30 d of screening;
• Status asthmaticus or severe asthma currently under treatment with acute doses of systemic corticosteroids, or severe chronic obstructive pulmonary disease requiring long-term oxygen therapy;
• Systolic blood pressure < 90 mm Hg, which cannot be adequately maintained with intravenous fluids and high-dose pressors;
• Intubation primarily for chronic interstitial lung disease (e.g., sarcoidosis, idiopathic pulmonary fibrosis);
• Any active air leak from the lung into the pleural space;
• Seizures refractory to anticonvulsant therapy;
• High risk of mortality within three months of screening for reasons other than ALI or ARDS or associated complications (e.g. terminal cancer with a high short-term risk of mortality);
• Hypersensitivity to perfluorocarbons;
• Pregnant females;
• Receipt of any other experimental drug within 30 d of screening;
• Significant renal dysfunction defined by (1) serum creatinine > 3.0 mg/dL or (2) an increase in serum creatinine of 0.8 mg/dL in 24 h;
• Significant hepatic dysfunction defined by serum total bilirubin > 2.0 mg/dL and albumin < 2.5 g/dL; or a prothrombin time 3 s greater than control or > 1.5 times the upper limit of normal and an activated partial thromboplastin time > 1.5 times the upper limit of normal;
• Significant haematologic dysfunction defined by platelet count < 75,000/mm 3 ; a total white blood cell count < 1000/µL; or evidence of disseminated intravascular coagulation; and
• In participants 46 to 90 y of age, high risk of mortality as defined by an APACHE II score ≥ 30.
Interventions
Randomly assigned to receive PLV or CMV for a maximum of four days for the first 45 participants and a maximum of five days for subsequent participants. Groups were allocated at a PLV-to-CMV ratio of 2:1. Perflurocarbon was administered at a dosage of 5 mL/kg increments based on ideal body weight to a maximum of 30 mL/kg. Each participant was assessed every four hours for the presence of a meniscus visible within the endotracheal tube during transient ventilator disconnect. If none was present, an additional 1 to 5 mL/kg aliquot of perflubron was administered. PLV was discontinued at the discretion of the investigator; no guidelines or rules regarding discontinuation of PLV were provided The mean duration of perflubron administration was 80 ± 3 h, with a range of 17 to 120 h Outcomes Primary outcome:
• VFDs to day 28. The initial primary outcome was oxygenation, but this was changed during the study to mean number of ventilator-free days to day 28. Ventilatorfree days to day 28 were defined as follows: "On Day 28, each survivor received 1 point for every day following discontinuation of mechanical ventilation, including the day of extubation, if the patient remained successfully weaned for the remainder of the day. Participants who died during the first 28 d of the study received a VFD score of zero. Participants who were re-intubated had days counted toward a VFD only if they remained off the ventilator for the remainder of the 28-day period. For instance, if a participant was extubated for two days and then re-intubated for the remainder of the 28 d, the VFD was zero. Only those days for which the participant was extubated and remained extubated for the remainder of the 28-day experimental period counted toward VFD" Secondary outcomes included:
• 28 day mortality;
• PaO 2 /FiO 2 ratio, A-a gradient; and • lung mechanics. Results: This study showed no difference in:
• number of ventilator-free days (CMV = 6.7 ± 1.8 d, PLV = 6.3 ± 1.0 d, P = 0.85);
• mortality at day 28 (CMV = 36%, PLV = 42%, P = 0.63); and • any pulmonary-related parameter. Adverse events: The authors do not provide P values or confidence intervals for all adverse event outcomes but report higher incidence of adverse events in those receiving PLV (99%) than in those receiving CMV (96%). Hypoxia, hypotension, pneumothoraces, bradycardia, respiratory acidosis and cardiac arrest were all more common in the partial liquid ventilation group Other relevant outcomes that were not reported:
The following outcomes, which we consider clinically relevant, were not reported:
• Mortality (at discharge from ICU, at discharge from hospital and at one, two and five years); 
Notes
There are some concerns with this study regarding the following: Methodological rigour and external validity: Concerns regarding methodological rigour and generalizability of results due to changes in selection criteria and primary endpoints during the course of the study and exclusion of patients with refractory shock and renal, hepatic and haematological dysfunction Adverse event reporting:
The authors conclude that "PLV may be performed reasonably safely in adult patients with respiratory failure with few adverse events, which appear to be transient, self limited and with appropriate vigilance, manageable". This statement does not accurately represent the findings of the study, which showed a higher incidence of hypoxia, hypotension, pneumothoraces, bradycardia and cardiac arrest in the partial liquid ventilation group, most of which occurred at times of perfluorocarbon dosing, and at least four episodes of cardiac arrest were attributable to treatment in this group Miscellaneous: A large number of post hoc analyses are reported. Post hoc analyses showed more rapid discontinuation of ventilation in the PLV arm (P = 0.045), although participants who were randomly assigned to PLV had a longer length of CMV before randomization (P = 0.12). The time lag involved may explain the difference in rapidity of discontinuation, as those randomly assigned later may already be in the recovery phase of their illness 18 centres were involved, although only 4 centres enrolled more than 5 participants of the total 90 participants
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk Quote: "Randomization was performed according to a 2 or 6 block design ..." Comment: Probably done, as although the authors do not tell us the exact method of randomization used, they do tell us that randomization was performed Allocation concealment (selection bias) Low risk Quote: "After granting of informed consent, a central office at Alliance Pharmaceutical was contacted for group assignment" Comment: Probably done, as a centralized randomization process is described Blinding (performance bias and detection bias) All outcomes
Unclear risk
Quotes:"This was a prospective, non blinded, randomized study…" "After entry of 45 patients evaluation of the data suggested a trend ...." "No monitoring committee was used" "There was no follow up to ensure that investigators adhered to these (ventilation) guidelines"
Comment: Not done, as the authors clearly state from the outset that no blinding was employed. The outcome measures addressed 'ventilator free days', '28 day mortality' and 'physiological indices' were objective and therefore were unlikely to be influenced by the lack of blinding. However, the fact that at least some of the investigators had access to unblinded interim data, together with the lack of any method of ensuring or measuring adherence to ventilation guidelines, raise concerns over possible performance bias
Blinding of outcome assessment (detection bias) All outcomes
Low risk There was no blinding of outcome measures, but the outcomes addressed were unambiguous and therefore were unlikely to be influenced significantly by the lack of blinding Incomplete outcome data (attrition bias) All outcomes
Low risk
The authors enrolled 90 participants but do not provide a statement of completeness of follow-up or any details of losses to follow-up. Results for primary and secondary outcomes are not presented in a way that allows the reader to determine whether all participants were followed up for the duration of the study However, adverse event data are presented in terms of absolute numbers, and for each event, these numbers add up to 90, so it is likely that all included participants were followed up for outcome Selective reporting (reporting bias) Unclear risk Quotes: "No significant difference in the number of days free from ventilation at 28 days, the incidence of mortality or any pulmonary related parameter was noted" "PLV may be performed safely in adult patients with respiratory failure with few ad- verse events, which appear to be transient, self limited and, with appropriate vigilance, manageable" Comments: The authors provide unbiased reports for the primary and secondary outcome measures of ventilator-free days and 28 day mortality. Both of these are clearly defined in the methods section of the report, and both are reported in an unbiased way However, the severity, seriousness and significance of adverse events are under-appreciated and under-reported
Other bias
Low risk Participants randomly assigned to the PLV group were randomly assigned an average of 25 h later than those who were randomly assigned to the CMV group However, this baseline imbalance in prerandomization of duration of ventilation is unlikely to have resulted in significant bias • Age younger than 16 or older than 65 y;
• Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥ 30;
• Longer than 48 h since meeting inclusion criteria;
• Inability to obtain informed consent;
• Significant nonpulmonary organ dysfunction as defined by the following:
• Chronic renal failure requiring dialysis;
• Acute liver disease with significant hepatocellular or cholestatic liver injury (acute hepatitis or acute cholestasis);
• Severe chronic liver disease (bilirubin > 3 mg/dL and serum albumin > 3 g/ dL); or
• Haematological dysfunction, defined by a total polymorphonuclear leukocyte (PMN) count < 0 .5 × 10 3 /mL.
• Systolic blood pressure < 90 mm Hg, unresponsive to treatment with fluids and 
vasopressors;
• Congestive heart failure, defined by a pulmonary arterial occlusion pressure >18 mm Hg or by clinical examination;
• Clinical history of decompensated left ventricular dysfunction as indicated by New York Heart Association Class III or IV or left ventricular ejection fraction < 30%;
• Documented myocardial infarction within the previous three months; or lifethreatening arrhythmia during the present hospital admission;
• Glasgow Coma Score < 10 determined before administration of confounding medications, such as narcotics, sedatives or neuromuscular blockers;
• Active air leak from the lung into the pleural space in the 24 h before randomization (chest tube to pleura vac with water seal without leak and not requiring suction for a minimum of 24 h was allowed);
• Evidence of increased intracranial pressure or history of an intracerebral haemorrhage within the previous three months;
• Status asthmaticus or severe asthma currently under treatment with pharmacological doses of intravenous corticosteroids;
• Chronic lung disease requiring long-term oxygen therapy or presenting with a baseline FEV 1 < 700 mL;
• Spinal cord injury above T-1;
• Myasthenia gravis or Guillain-Barre´syndrome or other neurological disorder that impairs the patient's ability to breath spontaneously;
• Organ transplantation (i.e. bone marrow, heart, lung, liver, kidney, pancreas);
• Acute parenchymal lung injury secondary to suspected overdose of narcotics;
• Burn injury (2nd or 3rd degree) with greater than 30% of total body surface area or with a restrictive chest injury;
• Life expectancy of < 3 months for other than ALI/ARDS-associated complications;
• Positive blood test for HIV with CD-4 count < 200;
• Received chemotherapy within 30 d before enrolment;
• Morbid obesity (more than twice ideal body weight); • Tracheostomy;
• Vascular lung disease with alveolar haemorrhage or pulmonary hypertension;
• Hypersensivity to perfluorocarbons;
• Positive serum β-human chorionic gonadotropin (HCG) indicating pregnancy; and
• Received any other experimental treatment within 30 d before screening (except nitric oxide, provided nitric oxide had been discontinued at least 4 h before initiation of standardized mechanical ventilation).
Interventions
Randomly assigned to receive:
• Conventional mechanical ventilation;
• Low-dose partial liquid ventilation instillation of PFC into the lungs to the level of the carina at zero-PEEP; or • High-dose partial liquid ventilation instillation of PFC into the lungs to an ETT level 5 cm below the incisors at zero-PEEP. Five participants did not receive the intended intervention (two randomly assigned to low-dose PLV and three randomly assigned to high-dose PLV never received PLV). 
